(Total Views: 708)
Posted On: 12/15/2020 4:20:41 PM
Post# of 145248
![](/m/assets/46931549/no_avatar_available_thumb.jpg)
CYDY: VANCOUVER, Washington, Dec. 15, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"
, a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today it had reached full enrollment in its Phase 3 registrational trial for patients with severe-to-critical COVID-19. The 390-patient data will be analyzed in approximately 28 days, with expected results to be announced shortly thereafter.
![](/m/images/icons/icon_wink.gif)
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)